

# Phosphorylation of Serine 1387 in Brca1 Is Specifically Required for the Atm-mediated S-Phase Checkpoint after Ionizing Irradiation<sup>1</sup>

Bo Xu, Anne H. O'Donnell, Seong-Tae Kim,<sup>2</sup> and Michael B. Kastan<sup>3</sup>

Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105

## Abstract

Although it is well established that inheritance of mutations in the *Brca1* gene significantly increases the chances of developing breast or ovarian cancers, the mechanisms underlying this specific tumor susceptibility remain to be clarified. It is clear that one of the roles of the *Brca1* protein is to facilitate cellular responses to DNA damage. We recently reported that *Brca1* function is required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G<sub>2</sub> phase of the cell cycle. We also found that mutation of serine 1423 in *Brca1*, a target of *Atm* phosphorylation, abrogates the G<sub>2</sub>-M checkpoint but not the ionizing irradiation-induced S-phase checkpoint. Here we demonstrate that mutation of serine 1387 in *Brca1*, another target of *Atm* phosphorylation, conversely abrogates the radiation-induced S-phase arrest but does not affect the G<sub>2</sub>-M checkpoint. Thus, these two posttranslational modifications of *Brca1* have two distinct functional roles in the protein. In addition, although mutation of this site abrogates the ionizing irradiation-induced S-phase arrest, it does not adversely affect cell survival after irradiation. This demonstrates that loss of this checkpoint function by itself does not affect cell survival and suggests that some other function of *Brca1* alters cell survival after DNA damage.

## Introduction

Progression through the cell cycle is inhibited when cellular DNA is damaged. It has been suggested that transient arrests in the G<sub>1</sub>, S, and G<sub>2</sub>-M phases of the cell cycle after DNA damage enhance cell survival and/or minimize genetic alterations (1–4). A number of different gene products have been demonstrated to be critical for inducing these cell cycle perturbations in mammalian cells after IR.<sup>4</sup> Arrests in all three of these cell cycle phases after IR require the *Atm* protein kinase (5–8). A variety of other gene products have been implicated in specific cell cycle arrests after IR, including p53, Chk2, and p21<sup>Waf1/Cip1</sup> in the G<sub>1</sub> checkpoint (9–11); Nbs1, *Brca1*, Smc1, Chk2, and Cdc25A in the S-phase checkpoint (8, 12–15); and *Brca1* and hRad17 in G<sub>2</sub>-M arrest (8, 16, 17).

Many of the proteins involved in these cell cycle perturbations are direct targets of the *Atm* protein kinase, including p53, Nbs1, Chk2, Smc1, and *Brca1*, and the sites of *Atm* phosphorylation are known for all of these substrates (12–15, 18–24). *Brca1* has an “SQ” cluster in the 244-amino acid region between amino acids 1280 and 1524, and

mass spectroscopic analysis has suggested that several of the serines in this region are phosphorylated after DNA damage (20). In particular, serines 1387, 1423, and 1524 appear to be phosphorylated by *ATM* in response to IR (20, 25). Phosphorylation of serine 1423 in *Brca1* appears to be important for the IR-induced G<sub>2</sub>-M checkpoint but is not required for the IR-induced S-phase arrest and is not a determinant of radiosensitivity (8, 17). However, although phosphorylation of serine 1423 in *Brca1* is not required for the IR-induced S-phase arrest, a functional *Brca1* protein is required for this checkpoint (8). Thus, it remained unclear how *Brca1* was involved in this *Atm*-dependent arrest.

Because serine 1387 in *Brca1* also appeared to be phosphorylated after IR (25), we investigated the potential role of this phosphorylation event in the IR-induced S-phase arrest. Acting as a dominant-negative activity, overexpression of a *Brca1* protein with serine 1387 mutated to alanine specifically abrogated the IR-induced S-phase arrest. Interestingly, overexpression of this mutant had a specific effect on *Brca1* function and did not affect the IR-induced G<sub>2</sub> arrest. Similarly, expression of this *Brca1* mutant protein in a cell line containing dysfunctional *Brca1* protein restored the defective G<sub>2</sub> checkpoint but did not complement the S-phase checkpoint. Interestingly, this mutant was as effective as wild-type *Brca1* in being able to reverse the decreased cell survival of this cell line after irradiation. This result supports prior demonstrations (17) that lack of the S-phase checkpoint by itself does not cause radiosensitivity. Furthermore, this result suggests that some function of *Brca1* protein that is not affected by phosphorylation of either serine 1387 or serine 1423 is an important determinant of cell survival after IR.

## Materials and Methods

**Cell Culture and Irradiation.** Human 293T cells that have normal IR-induced S-phase and G<sub>2</sub>-M checkpoints were grown as monolayers in DMEM supplemented with 10% fetal bovine serum. The human breast cancer cell line, HCC1937, which has a truncated, nonfunctional *Brca1* and which has defective IR-induced S-phase and G<sub>2</sub>-M checkpoints, was cultured in RPMI 1640 supplemented with 15% fetal bovine serum. All cell lines were grown at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. Radiation from a <sup>137</sup>Cs source was delivered at a dose rate of ~120 cGy/min.

**Expression of *BRCA1* Constructs in *Brca1* Mutant Cells.** Transfections of HA-tagged wild-type *BRCA1* (generously provided by David Livingston, Dana-Farber Cancer Institute, Boston, MA) or mutant *Brca1* constructs were performed transiently using Lipofectamine (Life Technologies, Inc., Rockville, MD). Expression of transfected *Brca1* was detected by Western blot analysis with an anti-HA monoclonal antibody (Roche Molecular Biochemicals, Indianapolis, IN). Transfection efficiencies were assessed by flow cytometric evaluation of GFP expression. For clonogenic survival assays in HCC 1937 cells transfected with *Brca1* constructs, 1 mg/ml of Geneticin (G-418; Life Technologies, Inc.) was added to the medium 36 h after transfection.

**G<sub>2</sub>-M Checkpoint Assay.** Cells were harvested at the indicated time points after IR and fixed in 70% ethanol at –20°C. The cells were suspended in 100 μl of PBS containing 1% BSA and 0.75 μg of a polyclonal antibody that specifically recognizes the phosphorylated form of histone H3 (Upstate Biotechnology, Lake Placid, NY) and incubated for 3 h at room temperature. The

Received 5/10/02; accepted 6/24/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by Grants CA71387, CA86861, and CA21765 from the NIH and by the American Lebanese Syrian Associated Charities of the St. Jude Children's Research Hospital. A. H. O. is a Professional Oncology Educational summer student from Tulane University, New Orleans, LA.

<sup>2</sup> Present address: Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute, 300 Chunchun-Dong, Changan-Ku, Suwon, Kyunggi-Do 440-746, Korea.

<sup>3</sup> To whom requests for reprints should be addressed, at Department of Hematology-Oncology, St. Jude Children's Research Hospital, 332 North Lauderdale St., Memphis, TN 38105. Phone: (901) 495-3968; Fax: (901) 495-3966; E-mail: Michael.Kastan@stjude.org.

<sup>4</sup> The abbreviations used are: IR, ionizing irradiation; GFP, green fluorescent protein; HA, hemagglutinin.




Fig. 1. Transfection of the serine 1387 mutant Brca1 abrogates the IR induced S-phase checkpoint. *A*, expression of HA-tagged Brca1 proteins in 293T cells was measured by immunoblot analysis with an anti-HA antibody. Levels of  $\beta$ -tubulin protein are shown as a loading control. *B*, transfection efficiency of the various Brca1 transgenes in 293T cells was assessed by flow cytometric analysis of expression of a cotransfected GFP vector. *C*, 30 min after exposure to 10 Gy of ionizing radiation, replicative DNA synthesis was measured in the 293T cells that had been transfected with either vector alone (*vector*), wild type (*wtBrca1*), or a series of serine-to-alanine mutants at the indicated sites (*S1378A*, *S1423A*, or *S1423/1524A*). Columns, averages of at least triplicate samples; bars, SE.

cells were then rinsed with PBS containing 1% BSA and incubated with fluorescein isothiocyanate-conjugated goat antirabbit IgG antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) diluted at a ratio of 1:30 in PBS containing 1% BSA. After a 30-min incubation at room temperature in the dark, the cells were stained with propidium iodide (Sigma), and cellular fluorescence was measured by a FACScalibur flow cytometer.

**S-Phase Checkpoint Assay.** Inhibition of DNA synthesis after irradiation was assessed as described previously (8, 12). Cells were prelabeled with 10 nCi of [ $^{14}$ C]thymidine (NEN Life Science Products, Inc., Boston, MA) for 24 h. Cells were irradiated and incubated for 30 min and then pulse-labeled with 2.5  $\mu$ Ci/ml [ $^3$ H]thymidine for 15 minutes (NEN Life Science Products). After harvesting, the amount of radioactivity was assayed in a liquid scintillation counter. The measure of DNA synthesis was derived from the resulting ratios of  $^3$ H cpm to  $^{14}$ C cpm, corrected for those cpm that resulted from channel crossover.

**Clonogenic Assays.** Cell lines were plated in triplicate into 6-well plates, incubated for 24 h, and then exposed to a range of doses of IR (0–6 Gy) followed by incubation for 2 weeks. Before counting the colonies, cells were fixed in 95% methanol and stained with crystal violet. A population of >50 cells were counted as one survived colony. The mean colony counts  $\pm$  SE appear in the figures.

## Results

**Brca1 Mutated at Serine 1387 Specifically Affects IR-induced S-Phase Arrest.** Brca1 is phosphorylated at several serine sites within its SQ cluster region in response to DNA damage. Among

those serine sites, ionizing irradiation appears to induce phosphorylation of serines 1387, 1423, and 1524 in an Atm-dependent manner (20, 25). We had observed previously that overexpression of a Brca1 protein with serine 1423 converted to alanine, a mutant unable to be phosphorylated on this site, and specifically inhibited the IR-induced G<sub>2</sub> arrest without adversely affecting the S-phase arrest and radiosensitivity that are also dependent on Brca1 function (8, 17). To begin to explore whether one of the other phosphorylation sites was an important determinant of the IR-induced S-phase checkpoint or radiosensitivity, a *Brca1* construct with serine 1387 mutated to alanine was constructed and transfected into 293T cells. In multiple experiments, the efficiency of transfection of this and other Brca1 constructs into 293 T cells was typically >90% in these cells (Fig. 1, *A* and *B*). Overexpression of this construct blocked the IR-induced S-phase checkpoint, thus inducing the phenomenon termed “radioresistant DNA synthesis” (Fig. 1*C*). In contrast, overexpression of *Brca1* constructs mutated at serine 1423 or both serines 1423 and 1524, although expressed at similar levels to the S1387A mutant (Fig. 1*A*), did not affect the IR-induced S-phase delay (Fig. 1*C*).

Similar conclusions were reached in complementation experiments using these mutants. HCC1937 cells that lack functional Brca1 protein are defective in the S-phase and G<sub>2</sub> arrests after IR and are radio-sensitive (8, 17). Efficiency of introduction of wild-type or mutant




Fig. 2. Mutation of serine 1387 abrogates complementation of the IR-induced S-phase checkpoint in Brca1-null cells. *A*, immunoblot analysis of expression of HA-tagged Brca1 proteins in the HCC1937 cells. Levels of  $\beta$ -tubulin protein are shown as a loading control. *B*, transfection efficiency in HCC1937 cells assessed by GFP expression as described in Fig. 1. *C*, 30 min after exposure to 10 Gy of ionizing radiation. Replicative DNA synthesis was measured in HCC1937 cells that had been complemented with the various HA-tagged Brca1 proteins.




Fig. 3. Phosphorylation of serine 1423, but not serine 1387, is required for the IR-induced G<sub>2</sub>-M checkpoint. **A**, flow cytometric profiles of cell cycle distribution before [IR (-)] or 1 h after 6 Gy ionizing irradiation [IR (+)]. Shown are HCC1937 cells expressing either vector alone (vector), wild type *Brca1* (wt*Brca1*), or a series of serine to alanine mutants at the indicated sites (S1387A, S1423A, or S1423/1524A). Staining for DNA content (propidium iodide; Y-axis) and for histone H3 phosphorylation (FITC-Histone H3p; X-axis) is presented. The mitotic cell population is encircled and labeled M. **B**, quantitative analysis of the flow cytometric data in **A**. Shown is the ratio (irradiated: un-irradiated) of the percentage of cells in mitosis. Columns, average of at least triplicate samples; bars, SE.

*Brca1* constructs into HCC1937 cells was reproducibly >80% in multiple experiments (Fig. 2, A and B). It is also noted that the cell cycle distributions without irradiation of neither 293T nor HCC1937 cells was affected by the transient overexpression of any of these *Brca1* constructs (Fig. 3A and data not shown). Wild-type *Brca1* and *Brca1* constructs mutated at either serine 1423 or both serines 1423 and 1524 all complemented the defective IR-induced S-phase delay in HCC1937 cells (Fig. 2C). In contrast, transfection of the serine 1387

*Brca1* mutant failed to complement this defect. However, the S1387A mutant was functional because it was able to complement the IR-induced G<sub>2</sub> checkpoint defect in these cells (Fig. 3). In confirmation of previous reports (8), although the S1423A and S1423A/S1524A mutants were capable of restoring the IR-induced S-phase delay, these constructs failed to restore the IR-induced G<sub>2</sub> arrest (Fig. 3).

**Dissociation of Radiation Sensitivity from IR-induced Cell Cycle Checkpoint Defects.** Disruption of the IR-induced G<sub>2</sub> checkpoint in yeast appears to reduce cell survival (1). To help clarify the relationships between IR-induced cell cycle arrests and cell survival in human cells, clonogenic assays were performed in HCC1937 cells expressing the various *Brca1* constructs. The parental HCC1937 cells are relatively radiosensitive, and re-introduction of wild-type *Brca1* decreases the radiation sensitivity (Fig. 4). However, introduction of either the S1387A construct (a situation in which the S-phase checkpoint is defective) or the S1423A or S1423A/1524A constructs (a situation in which the G<sub>2</sub>-M checkpoint is defective) all decreased radiosensitivity as effectively as the wild-type *Brca1* construct (Fig. 4). Thus, the radiosensitivity of these *Brca1*-defective cells is not attributable to the defects in IR-induced cell cycle arrests.

## Discussion

Among the mechanisms developed by eukaryotic cells to optimally respond to DNA damage are cell cycle arrests or checkpoints. These perturbations of cell cycle progression presumably enhance genetic stability and limit tumorigenesis in the organism. The fact that so many familial cancer syndromes result from dysfunction of genes involved in checkpoint responses (e.g., p53, Chk2, Atm, *Brca1*, Nbs1; Ref. 26) supports this concept. The Atm protein kinase is activated by ionizing irradiation and through phosphorylation of a number of different protein substrates appears to initiate multiple cell cycle arrests (26, 27). The *Brca1* protein is one of these substrates, and cells defective in *Brca1* functions lack both the transient S-phase and G<sub>2</sub> arrests that should be initiated by ionizing irradiation. In the present study, we extend these insights by demonstrating that phosphorylation of *Brca1* on serine 1387 is required for the transient S-phase arrest, but not the G<sub>2</sub> arrest, after IR. Conversely, phosphorylation of serine 1423 is required for the G<sub>2</sub> arrest, but not the S-phase arrest, after IR (8).




Fig. 4. Abrogation of either the S-phase or G<sub>2</sub>-M cell cycle checkpoints is not sufficient to increase radiation sensitivity. Colony formation assays were performed in HCC1937 cells expressing either vector alone (vector), wild type (*Brca1*), or a series of serine to alanine mutants at the indicated sites (S1387A, S1423A, or S1423/1524A). Surviving fractions are plotted on a log scale (Y-axis) versus dose of IR (X-axis). Data are the averages of at least triplicate samples; bars, SE.

Thus, two different IR-induced phosphorylation events in the same molecule have two different functional consequences. It is not known whether these phosphorylation events are cell cycle stage specific or whether they occur on the same protein molecule. These are questions appropriate for future studies.

Identification of specific posttranslational modifications that affect specific cell cycle checkpoints also allow us to investigate the impact that specific checkpoint defects have on cellular outcome after irradiation. In this case, selective mutations of Brca1 allow us to specifically abrogate either the IR-induced S-phase or G<sub>2</sub> checkpoints. The data presented here demonstrate that neither selective abrogation of the S-phase checkpoint nor the G<sub>2</sub> checkpoint enhances radiosensitivity. Because the p53 gene is mutated in HCC1937 cells, the G<sub>1</sub> cell cycle checkpoint is also defective in these cells. Thus, our data suggest that even disruption of two cell cycle checkpoints (G<sub>1</sub> plus S, or G<sub>1</sub> plus G<sub>2</sub>) is not sufficient to enhance radiation sensitivity. Previous experiments have demonstrated that cells with mutant p53 appear to demonstrate enhanced radiosensitivity when treated with the chemicals caffeine or UCN-01 (28–30). Because these compounds block the G<sub>2</sub> checkpoint, it was suggested that this enhanced radiosensitivity was caused by abrogating the G<sub>2</sub> checkpoint in cells that already had G<sub>1</sub> checkpoint abnormalities. The data shown here demonstrate that radiosensitivity caused by UCN-01 and caffeine must result from some cellular effect of these compounds other than their effect on the G<sub>2</sub> checkpoint itself. A similar line of reasoning leads to the conclusion that some function of Brca1 protein other than S-phase or G<sub>2</sub> cell cycle control affects cell survival after ionizing irradiation. What this function is remains to be determined. Finally, it must be pointed out that these studies do not address the Brca1 function that is critical for preventing breast or ovarian cancer. The Brca1 activity that is relevant to its tissue-specific tumor suppressor function must still be clarified. However, these insights do have potential relevance for understanding or modulating the responses of tumors with Brca1 dysfunction to therapeutic intervention and should allow us to further dissect the various activities of this complex multifunctional protein.

## Acknowledgments

We gratefully acknowledge the technical assistance of Diane Woods and Margaret Reis. We thank all members of the Kastan laboratory for helpful discussions and David Livingston for providing the wild-type *BRCA1* cDNA.

## References

- Hartwell, L. H., and Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. *Science (Wash. DC)*, *246*: 629–634, 1989.
- Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. *Science (Wash. DC)*, *266*: 1821–1828, 1994.
- Elledge, S. J. Cell cycle checkpoints: preventing and identity crisis. *Science (Wash. DC)*, *274*: 1664–1672, 1996.
- Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes Dev.*, *15*: 2177–2196, 2001.
- Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell*, *71*: 587–597, 1992.
- Morgan, S. E., Lovly, C., Pandita, T. K., Shiloh, Y., and Kastan, M. B. Fragments of ATM which have dominant-negative or complementing activity. *Mol. Cell. Biol.*, *17*: 2020–2039, 1997.
- Ziv, Y., Bar-Shira, A., Pecker, I., Russell, P., Jorgensen, T. J., Tsarfati, I., and Shiloh, Y. Recombinant ATM protein complements the cellular A-T phenotype. *Oncogene*, *15*: 159–167, 1997.
- Xu, B., Kim, S.-T., and Kastan, M. B. Involvement of Brca1 in S-phase and G<sub>2</sub>-phase checkpoints after ionizing irradiation. *Mol. Cell. Biol.*, *21*: 3445–3450, 2001.
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.*, *51*: 6304–6311, 1991.
- Chehab, N. H., Malikzay, A., Appel, M., and Halazonetis, T. D. Chk2/hCds1 functions as a DNA damage checkpoint in G<sub>1</sub> by stabilizing p53. *Genes Dev.*, *14*: 278–288, 2000.
- El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. *Cell*, *75*: 817–825, 1993.
- Lim, D.-S., Kim, S.-T., Xu, B., Maser, R. S., Lin, J., Petrini, J. H. J., and Kastan, M. B. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. *Nature (Lond.)*, *404*: 613–617, 2000.
- Kim, S. T., Xu, B., and Kastan, M. B. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. *Genes Dev.*, *16*: 560–570, 2002.
- Yazdi, P. T., Wang, Y., Zhao, S., Patel, N., Lee, E. Y., and Qin, J. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. *Genes Dev.*, *16*: 571–582, 2002.
- Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J., and Lukas, J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. *Nature (Lond.)*, *410*: 842–847, 2001.
- Bao, S., Tibbetts, R. S., Brumbaugh, K. M., Fang, Y., Richardson, D. A., Ali, A., Chen, S. M., Abraham, R. T., and Wang, X.-F. ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. *Nature (Lond.)*, *411*: 969–974, 2001.
- Xu, B., Kim, S. T., Lim, D. S., and Kastan, M. B. Two molecularly distinct G<sub>2</sub>/M checkpoints are induced by ionizing irradiation. *Mol. Cell. Biol.*, *22*: 1049–1059, 2002.
- Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science (Wash. DC)*, *281*: 1677–1679, 1998.
- Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. *Science (Wash. DC)*, *281*: 1674–1677, 1998.
- Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. *Science (Wash. DC)*, *286*: 1162–1166, 1999.
- Ahn, J.-Y., Schwarz, J. K., Pivnicka-Worms, H., and Canman, C. E. Threonine 68 phosphorylation by ATM is required for efficient activation of Chk2 in response to ionizing radiation. *Cancer Res.*, *60*: 5934–5936, 2000.
- Matsuoka, S., Huang, M., and Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science (Wash. DC)*, *282*: 1893–1897, 1998.
- Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., and Elledge, S. J. Ataxia telangiectasia-mutated phosphorylates Chk2 *in vivo* and *in vitro*. *Proc. Natl. Acad. Sci. USA*, *97*: 10389–10394, 2000.
- Melchionna, R., Chen, X.-B., Blasina, A., and McGowan, C. H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. *Nat. Cell Biol.*, *2*: 762–765, 2000.
- Gatei, M., Zhou, B. B., Hobson, K., Scott, S., Young, D., Khanna, K. K. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. *In vivo* assessment using phospho-specific antibodies. *J. Biol. Chem.*, *276*: 17276–17280, 2001.
- Kastan, M. B., and Lim, D.-S. The many substrates and functions of ATM. *Mol. Cell. Biol.*, *1*: 179–186, 2000.
- Shiloh, Y., and Kastan, M. B. ATM: genome stability, neuronal development, and cancer cross paths. *Adv. Cancer Res.*, *83*: 209–254, 2001.
- Powell, S. M., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F., Dombkowski, D., Tang, W., and Friend, S. Differential sensitivity of p53<sup>(-/-)</sup> and p53<sup>(+/+)</sup> cells to caffeine-induced radiosensitization and override of G<sub>2</sub> delay. *Cancer Res.*, *55*: 1643–1648, 1995.
- Russell, K. J., Wiens, L. W., Demers, G. W., Galloway, D. A., Plon, S. E., and Groudine, M. Abrogation of the G<sub>2</sub> checkpoint results in differential radiosensitization of G<sub>1</sub> checkpoint-deficient and G<sub>1</sub> checkpoint-competent cells. *Cancer Res.*, *55*: 1639–1642, 1995.
- Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., and O'Connor, P. M. UCN-01: a potent abrogator of G<sub>2</sub> checkpoint function in cancer cells with disrupted p53. *J. Natl. Cancer Inst.*, *88*: 956–965, 1996.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Phosphorylation of Serine 1387 in Brca1 Is Specifically Required for the Atm-mediated S-Phase Checkpoint after Ionizing Irradiation

Bo Xu, Anne H. O'Donnell, Seong-Tae Kim, et al.

*Cancer Res* 2002;62:4588-4591.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/62/16/4588>

**Cited articles** This article cites 29 articles, 20 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/62/16/4588.full#ref-list-1>

**Citing articles** This article has been cited by 37 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/62/16/4588.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/62/16/4588>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.